Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.41 |
| ▸ | THRB | P10828 | 12/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6343976 | 0.91 | MEN1 (0.50) | MEN1NR1I2KMT2AP2RX7THRB | |
| SCHEMBL5567074 | 0.89 | THRB (0.39) | MEN1NR1I2KMT2AP2RX7THRB | |
| SCHEMBL5566710 | 0.80 | P2RX7 (0.41) | MEN1NR1I2KMT2AP2RX7THRB | |
| SCHEMBL5561098 | 0.80 | MEN1 (0.48) | MEN1NR1I2KMT2AP2RX7THRB | |
| SCHEMBL6455630 | 0.78 | MEN1 (0.45) | MEN1NR1I2KMT2AP2RX7THRB | |
| SCHEMBL7138795 | 0.78 | MEN1 (0.46) | MEN1NR1I2KMT2AP2RX7THRB | |
| SCHEMBL6455399 | 0.77 | MEN1 (0.49) | MEN1NR1I2KMT2AP2RX7THRB | |
| SCHEMBL10667190 | 0.76 | MEN1 (0.55) | MEN1NR1I2KMT2AP2RX7THRB | |
| SCHEMBL7890517 | 0.75 | THRB (0.41) | MEN1NR1I2KMT2AP2RX7THRB | |
| SCHEMBL6462786 | 0.73 | P2RX7 (0.44) | MEN1NR1I2KMT2AP2RX7THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000040-B1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | EP | disclosed |
| US-20050090495-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | LACRAMPE JEAN FERNAND ARMAND (FR) | 2005-04-28 | — | — | US | disclosed |
| US-20020072603-A1 | Novel IL-5 inhibiting 6-azauracil derivatives | LACRAMPE JEAN FERNAND ARMAND (FR) | 2002-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090495-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | CXCR5, HCAR3, IL6ST | MEN1 3111/4885NR1I2 211/4885KMT2A 4590/4885 |
| US-20020072603-A1 | Novel IL-5 inhibiting 6-azauracil derivatives | IL6ST, ALOX5, IL5 | MEN1 4683/4885NR1I2 266/4885KMT2A 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.